Congress expands opioid treatment funding through 2030, targets fentanyl crisis.
H.R. 2483 — SUPPORT for Patients and Communities Reauthorization Act of 2025 · Filed by Brett Guthrie (R-KY) · 1 cosponsor · Introduced Mar 31, 2025 · Signed
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill reauthorizes and expands federal programs addressing opioid use disorder, substance abuse, and related mental health issues through 2030. It funds prevention, treatment, and recovery initiatives including grants to states and tribes, training for healthcare providers, support for pregnant women with substance use disorders, peer recovery services, and cybersecurity protections for the national suicide prevention lifeline. The bill also adds new provisions on fentanyl contamination awareness, at-home drug disposal, and workforce development for addiction treatment providers.
Why we flagged it
The bill's primary function is to reauthorize and expand existing federal grant programs and initiatives addressing opioid use disorder, substance abuse, and mental health treatment through appropriations and program modifications. It is a straightforward public health reauthorization with multiple technical amendments.
What the text implies
- Section 209 directs HHS to review the scheduling of buprenorphine/naloxone combination products and potentially request rescheduling by the Attorney General, which could expand access to these medications if reclassified to a lower schedule.
- Section 210 expands references to 'opioid overdose reversal drugs' beyond naloxone to include newly FDA-approved alternatives, potentially benefiting manufacturers of newer reversal agents.
The full analysis lists 5 implications of this text.
Who stands to gain
State and tribal health agencies; Nonprofit community health organizations; Academic medical centers and research institutions